Opus Bio Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Private

  • Employees
  • 30

Employees

  • Latest Deal Type
  • Buyout/​LBO

  • Financing Rounds
  • 2

Opus Bio General Information

Description

Developer of lentiviral gene delivery products intended for therapeutic, vaccine and bioproduction applications. The company develops a lentiviral vectors technology platform for the delivery of genetic sequence information into cells to reprogram their function and is applicable across epithelial cancers, thereby assisting with the identification of promising early-stage innovative therapeutic candidates and enhancing patient outcomes.

Contact Information

Website
www.opusbio.com
Formerly Known As
Lentigen
Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Corporate Office
  • Greenwich, CT
  • United States
Primary Industry
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Greenwich, CT
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Opus Bio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Opus Bio‘s full profile, request access.

Request a free trial

Opus Bio Patents

  • 400

    Total Documents Applications and Grants

  • Total Patents Families

  • 246

    Granted

  • 95

    Pending

  • Expiring in next 12 mo

Opus Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260000765-A1 Chimeric antigen receptor therapies for treating cancer with il7fc armored car-t cells Pending 27-Jun-2024
WO-2026006682-A1 Chimeric antigen receptor therapies for treating cancer with il7fc armored car-t cells Pending 27-Jun-2024
AU-2023329412-A1 Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy Pending 26-Aug-2022
EP-4577571-A1 Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy Pending 26-Aug-2022
JP-2025529917-A Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy Pending 26-Aug-2022 A61K40/31
To view Opus Bio’s complete patent history, request access »

Opus Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Opus Bio FAQs

  • When was Opus Bio founded?

    Opus Bio was founded in 2004.

  • Where is Opus Bio headquartered?

    Opus Bio is headquartered in Greenwich, CT.

  • What is the size of Opus Bio?

    Opus Bio has 30 total employees.

  • What industry is Opus Bio in?

    Opus Bio’s primary industry is Biotechnology.

  • Is Opus Bio a private or public company?

    Opus Bio is a Private company.

  • What is the current valuation of Opus Bio?

    The current valuation of Opus Bio is .

  • What is Opus Bio’s current revenue?

    The current revenue for Opus Bio is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process